Metabolic Shift-Enabled Industrial Applications

Publication ID: 24-11857573_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Metabolic Shift-Enabled Industrial Applications,” Published Technical Disclosure No. 24-11857573_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857573_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,573.

Summary of the Inventive Concept

This inventive concept leverages the core technology of restimulating cryopreserved tumor infiltrating lymphocytes to develop novel solutions for various industries, including solar panel manufacturing, electric vehicle batteries, food preservation, skincare, and fuel cells.

Background and Problem Solved

The original patent focused on the treatment of bulky, refractory cancers using adoptive transfer of tumor infiltrating lymphocytes (TILs). However, the metabolic shift principles and restimulation protocol disclosed in the patent have broader implications. This inventive concept addresses the limitations of existing solutions in various industries by applying the core technology to enhance performance, efficiency, and shelf life.

Detailed Description of the Inventive Concept

The newly generated claims describe methods and systems that adapt the restimulation protocol to improve the efficiency of solar panel manufacturing, monitor and optimize electric vehicle battery health, increase the shelf life of perishable food products, develop personalized skincare products, and enhance fuel cell performance. These applications capitalize on the metabolic shift principles to optimize the performance of photovoltaic cells, microorganisms, skin cells, and fuel cells. The inventive concept involves the restimulation of cryopreserved cells or microorganisms to enhance their metabolic activity, leading to improved outcomes in the respective industries.

Novelty and Inventive Step

The novelty of this inventive concept lies in the unexpected application of the restimulation protocol to industries unrelated to cancer treatment. The inventive step involves the recognition of the broader potential of the metabolic shift principles and the adaptation of the restimulation protocol to address specific problems in various industries.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the restimulation protocol, such as adjustments to the cryopreservation process, changes in the composition of the dissociated tumor materials, or modifications to the metabolic shift principles. Additionally, the inventive concept could be applied to other industries, such as agriculture, biotechnology, or environmental remediation.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including renewable energy, electric vehicles, food technology, cosmetics, and energy storage. The market for these applications is substantial, with potential customers ranging from manufacturers and suppliers to consumers and end-users.

Original Patent Information

Patent NumberUS 11,857,573
TitleRestimulation of cryopreserved tumor infiltrating lymphocytes
Assignee(s)Iovance Biotherapeutics, Inc.